New lupus medications (YKST02 with or without YK012)
Part of Immune system & allergy, Skin clinical trials.
This study tests two new experimental medications designed to calm the immune system in patients with systemic lupus erythematosus (SLE)—an autoimmune disease where the body attacks its own tissues. You may qualify if your lupus is still active despite taking standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed SLE diagnosis with active disease (a score of 6 or higher on a lupus activity scale)
- Have tried standard lupus medications for at least 12 weeks, or cannot tolerate them
- Currently stable on background lupus medications (steroids, antimalarial, or immunosuppressant)
- Have specific lupus antibodies in your blood (anti-dsDNA, antinuclear antibody, or anti-Smith)
- Not pregnant or breastfeeding, and willing to use contraception if needed
- No recent B-cell targeting biologics or other experimental drugs within washout period
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, YK012, for people with moderate to severe lupus. It aims to see if the drug can reduce disease activity and improve symptoms.
This trial tests a new medicine called SYS6020 for people whose lupus is still active despite standard treatments. It aims to see if the drug can help reduce lupus activity.
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
This study tests a new medicine, IMC-002, for people with active lupus that hasn't been controlled by standard treatments. It aims to see if the drug can reduce lupus activity and improve symptoms.
This study tests a new investigational drug called SCTB35 for people with active systemic lupus erythematosus (SLE or lupus). It aims to see if the drug is safe and effective in controlling lupus activity when added to your current stable lupus medications.
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity in conditions like lupus, Sjögren's syndrome, and others.
Hear when a new System Lupus Erythematosus(SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.